ClinicalTrials.gg
RecruitingNCT07683754DB-GuideUpdated Oct 16, 2026

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

A Phase 3 interventional study of Trastuzumab deruxtecan and Trastuzumab in Advanced Breast Cancer, Metastatic Breast Cancer and HER2 Positive, sponsored by Daiichi Sankyo. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Planned enrollment
21st of 58
200 · median 139
Started
2026
with 9 others
Phase 3
12 of 58
3 open now
Primary completion
2030-07
later than 42 of 44 live
Registered
55th of 58
by date
Lead sponsor
9 of 58
Daiichi Sankyo

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 21st largest by planned enrollment, is one of 10 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 42 of the 44 other live ones, and was the 55th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under maintenance aimed to maximizing disease control, optimizing tolerability, and preserving T-DXd as a future therapeutic option, while ensuring participant safety and regulatory compliance in participants with HER2+/HR+ advanced/metastatic breast cancer.

Read the detailed description

This global, interventional, open-label, phase 3b trial will evaluate the efficacy and safety of a sequential treatment approach for first-line HER2+/HR+ advanced/metastatic breast cancer, initiating with upfront T-DXd + pertuzumab administered for 18 to 24 cycles, followed by a transition to trastuzumab + pertuzumab + ET + palbociclib. Participants who experience disease progression while receiving trastuzumab + pertuzumab + ET + palbociclib will receive T-DXd as 2L therapy.

The study objectives will assess efficacy, safety, and quality-of-life in patients with advanced/metastatic breast cancer.

03

Conditions studied

  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • HER2 Positive
  • HR Positive

Browse trials for

Keywords

  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • T-DXd
  • HER2 positive
  • HR positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria for Upfront Treatment Phase

  1. Sign and date the Main Trial form (ICF), prior to the start of any trial-specific procedures.
  2. Participant must be ≥18 years of age at the time the ICF is signed.
  3. Have documented breast cancer that:

    • Is locally advanced and unresectable or (participants who can be treated with curative intent are not eligible).
    • Participant must have histologically confirmed + and HR+ (ER+ and/or PR+), mBC. ER, PR, and HER2 measurements should be locally performed according to institutional guidelines.
    • Is documented by local testing as HR-positive (either ER and/or PgR positive [ER or PgR ≥1%]) per ASCO/CAP guidelines in the metastatic setting or from the primary tumor with the latest sample available.
  4. Has not received prior chemotherapy or HER2-targeted therapy for mBC. Participant who has received chemotherapy or HER2-targeted therapy or radiotherapy or surgery in the or adjuvant setting are eligible, with a DFI of >6 months (>183 days) from completion of systemic chemotherapy or any HER2-targeted therapy (antibody, TKI or T-DM1) to diagnosis of advanced or metastatic disease.
  5. PS of 0 or 1 assessed no more than 3 days prior to initiation of trial intervention.
  6. Has at least 1 lesion, not previously irradiated, that can be measured accurately at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with CT or MRI, which is suitable for accurate repeated measurements, or nonmeasurable, bone-only disease that can be assessed by CT, MRI, or X-ray.
  7. Participant with are allowed if participant is asymptomatic and does not require immediate local intervention.

Additional Key Criteria to Transition into the Maintenance Treatment Phase

1. Participant transitioning into the Maintenance Treatment Phase must meet the following inclusion criteria for Maintenance Treatment:

  • Participant is without evidence of disease progression under T-DXd + pertuzumab treatment by local assessment according to v1.1 (ie, CR, PR, or SD), and
  • Participant is willing to switch therapy, and
  • Participant completed at least 8 cycles of T-DXd + pertuzumab and achieved cCR (confirmation of CR should be obtained during the next protocol defined scheduled tumor assessment.), or
  • Participant completed 18 cycles (in total) of T-DXd and achieved a SD or PR, and the last 2 scans showed no further tumor shrinkage (defined as 2 subsequent scans at least 6 weeks apart) or has an unconfirmed CR.

Additional Key Criteria for T-DXd Retreatment Phase

  1. Has received at least 1 dose of Maintenance Treatment.
  2. Has documented disease progression per RECIST v1.1 per investigator assessment during Maintenance Treatment.
  3. Participant who experienced ILD Grade 1 during the Maintenance Treatment Phase, must have fully resolved before starting T-DXd during the Retreatment Phase.

Key Exclusion Criteria for Upfront Treatment Phase

  1. Has prior therapy with any CDK inhibitor.
  2. Previous T-DXd therapy for early BC with an EFS or disease-free interval of \< 12 months from completion of T-DXd therapy in the neoadjuvant or post-neoadjuvant setting.

Key Exclusion Criteria for Maintenance Treatment Phase

  1. Is receiving concurrent therapy with other trial interventions (except pertuzumab which is part of Upfront Treatment and Maintenance Treatment).
  2. Has prior therapy with any CDK inhibitor.
  3. Has any unresolved SAE related to prior T-DXd + pertuzumab treatment from the Upfront Treatment Phase, defined as an event that has not resolved to baseline by the time of the eligibility assessment for the Maintenance Treatment Phase.
  4. Has experienced Grade 3 or 4 ILD/pneumonitis during the Upfront Treatment Phase.
  5. Has spinal cord compression or clinically active CNS metastases, defined as untreated or symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms.

Key Exclusion Criteria for T-DXd Retreatment Phase

  1. Participant who developed ILD/pneumonitis Grade ≥2 during the Upfront Treatment Phase or Maintenance Treatment Phase.
  2. Participant has any unresolved SAE related to prior Maintenance Treatment Phase therapies defined as an event that has not resolved to baseline by the time of the eligibility assessment for the T-DXd Retreatment Phase.
  3. Participant who developed non-ILD toxicities related to T-DXd in the Upfront Treatment Phase that required T-DXd discontinuation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    T-DXd

    Adult participants with previously untreated advanced or metastatic HER2+/HR+ breast cancer who will receive T-DXd intravenously every 3 weeks (IV Q3W) in 3 treatment phases: Upfront treatment phase: T-DXd + pertuzumab IV Q3W Maintenance treatment phase: Trastuzumab + palbociclib + endocrine therapy + pertuzumab IV Q3W T-DXD retreatment phase: T-DXd monotherapy IV Q3W

    Drug: Trastuzumab deruxtecan · Drug: Trastuzumab · Drug: Pertuzumab · Drug: Endocrine Therapy · Drug: Palbociclib

Interventions

  • Upfront treatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle T-DXd Retreatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle \*Dose reductions implemented during Upfront treatment phase will be maintained.

    Also known as: T-DXd, ENHERTU®

  • Maintenance treatment: One IV infusion Q3W 6 mg/kg on Day 1 of each 21-day cycle

    Also known as: Herceptin®

  • Upfront treatment: One IV infusion Q3W loading dose of 840 mg, then 420 mg Q3W thereafter on Day 1 of each 21-day cycle Maintenance treatment: One IV infusion Q3W 420 mg on Day 1 of each 21-day cycle

    Also known as: Perjeta®

  • DrugEndocrine Therapy

    Aromatase inhibitors or fulvestrant administered as approved product label

  • Maintenance treatment: Daily (3 out of 4 weeks, Q4W) oral 125 mg

    Also known as: Ibrance®

This study also gives Fulvestrant. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Rate at 24 Months

    PFS is defined as the time from initiation of T-DXd + pertuzumab until PD or death, whichever occurs first.

    Time frame: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months

Secondary outcomes

  1. Progression-free Survival (PFS) Rate at 12 Months

    PFS is defined as the time from initiation of T-DXd + pertuzumab until PD or death, whichever occurs first.

    Time frame: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 12 months

  2. Objective Response Rate

    ORR is defined as the proportion of participants with measurable disease at baseline who have a CR or PR during the Upfront Treatment Phase.

    Time frame: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months

  3. Progression-free Survival (PFS) Rate From Start of Maintenance Treatment at 12 Months

    PFS from start of Maintenance Treatment is defined as the time from initiation of Maintenance Treatment until PD or death, whichever occurs first.

    Time frame: From start of Maintenance Treatment until disease progression (PD) or death, whichever occurs first, up to approximately 12 months

  4. Overall Survival at 24 Months

    OS is defined as the time from initiation of T-DXd + pertuzumab until the date of death due to any cause.

    Time frame: From start of Upfront Treatment phase until the date of death, up to approximately 24 months

  5. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), and Death

    Time frame: From start of T-DXd Retreatment phase up to approximately 24 months

  6. Time to First AESI and TEAE

    Time frame: From start of T-DXd Retreatment phase up to approximately 24 months

  7. Objective Response Rate

    Time frame: From start of T-DXd Retreatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months

  8. Change From Maintenance Treatment Baseline in EORTC-QLQC30 Global Health Score, Functional, and Symptom Scales.

    The EORTC-QLQ-C30 includes both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high-level of symptomatology/problems.

    Time frame: From start of Maintenance Treatment phase until approximately 24 months

  9. Change From Maintenance Treatment Baseline in EQ-5D-5L Overall Score

    The EQ-5D-5L questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, participants select the statement that best describes their health on that day from 5 levels of increasing severity: "No problems", "Slight problems", "Moderate problems", "Severe problems", and "Unable to / Extreme problems", with higher levels indicating worse severity. A unique health state (EQ-5D-5L profile) is defined by the combination of responses across the 5 dimensions and is represented as a five-digit code. The EQ-5D-5L profile will be converted into a health state utility index value reported here.

    Time frame: From start of Maintenance Treatment phase until approximately 24 months

  10. Change From Maintenance Treatment Baseline in EQ-5D-5L Dimension-specific Scores

    The EQ-5D-5L questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, participants select the statement that best describes their health on that day from 5 levels of increasing severity: "No problems", "Slight problems", "Moderate problems", "Severe problems", and "Unable to / Extreme problems", with higher levels indicating worse severity.

    Time frame: From start of Maintenance Treatment phase until approximately 24 months

  11. Change From Maintenance Treatment Baseline in EQ-VAS

    The EQ-VAS records the participant's self-rated health on a vertical visual analogue scale ranging from 0 to 100, where: 0 represents "the worst imaginable health", and 100 represents "the best imaginable health". Higher scores indicate worse clinical outcome.

    Time frame: From start of Maintenance Treatment phase until approximately 24 months

  12. Time to Deterioration/Improvement After the Transition to Maintenance Treatment Phase

    Time frame: From start of Maintenance Treatment phase until approximately 24 months

  13. Change From Upfront Treatment Baseline in EORTC-QLQC30 Global Health Score, Functional, Symptom Scales.

    The EORTC-QLQ-C30 includes both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high-level of symptomatology/problems.

    Time frame: From start of Upfront Treatment phase to end of Maintenance Treatment phase, up to approximately 24 months

  14. Change From Upfront Treatment Baseline in EQ-5D-5L Overall Score

    The EQ-5D-5L questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, participants select the statement that best describes their health on that day from 5 levels of increasing severity: "No problems", "Slight problems", "Moderate problems", "Severe problems", and "Unable to / Extreme problems", with higher levels indicating worse severity. A unique health state (EQ-5D-5L profile) is defined by the combination of responses across the 5 dimensions and is represented as a five-digit code. The EQ-5D-5L profile will be converted into a health state utility index value reported here.

    Time frame: From start of Upfront Treatment phase through end of Maintenance Treatment phase, up to approximately 24 months

  15. Change From Upfront Treatment Baseline in EQ-5D-5L Dimension-specific Scores

    The EQ-5D-5L questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, participants select the statement that best describes their health on that day from 5 levels of increasing severity: "No problems", "Slight problems", "Moderate problems", "Severe problems", and "Unable to / Extreme problems", with higher levels indicating worse severity.

    Time frame: From start of Upfront Treatment phase through end of Maintenance Treatment phase, up to approximately 24 months

  16. Change From Upfront Treatment Baseline in EQ-VAS

    The EQ-VAS records the participant's self-rated health on a vertical visual analogue scale ranging from 0 to 100, where: 0 represents "the worst imaginable health", and 100 represents "the best imaginable health". Higher scores indicate worse clinical outcome.

    Time frame: From start of Upfront Treatment phase through end of Maintenance Treatment phase, up to approximately 24 months

  17. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), and Death

    Time frame: From start of Upfront Treatment phase up to approximately 24 months

  18. Time to First AESI and TEAE

    Time frame: From start of Upfront Treatment phase up to approximately 24 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2030, 45 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 45 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 6, 2026
StartActual
Sep 18, 2026
Primary completionEst.
Jul 4, 2030
CompletionEst.
Aug 28, 2030
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
5 sites added — first site in United States
Show 5 added (5 United States)
  • Maryland Oncology Hematology, P.A. · Columbia, United States
  • Comprehensive Cancer Centers of Nevada · Las Vegas, United States
  • SCRI Oncology Partners · Nashville, United States
  • Texas Oncology - West Texas · El Paso, United States
  • Texas Oncology - San Antonio · New Braunfels, United States
Oct 16, 2026
Start date
Sep 4, 2026→Sep 18, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    5 sites added — first site in United States
    Show 5 added (5 United States)
    • Maryland Oncology Hematology, P.A. · Columbia, United States
    • Comprehensive Cancer Centers of Nevada · Las Vegas, United States
    • SCRI Oncology Partners · Nashville, United States
    • Texas Oncology - West Texas · El Paso, United States
    • Texas Oncology - San Antonio · New Braunfels, United States
    Start date Sep 4, 2026→Sep 18, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07683754
Lead sponsor
Daiichi Sankyo
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Sep 18, 2026
Primary completion
Jul 4, 2030 (estimated)
Completion
Aug 28, 2030 (estimated)
Last update
Oct 16, 2026

Study contacts

Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion